SPDR S&P Pharmaceuticals ETF Rating $58.86 -0.24 (-0.41%) As of 05/14/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy 2.62Holdings in XPH have an aggregate rating of Moderate Buy based on 239 analyst ratings issued in the past year covering 25 companies (54.7% of the portfolio).XPH Aggregate Price Target$58.86High Prediction$58.86Average Prediction$58.86Low Prediction$58.86Holdings in XPH have an aggregate price target of $58.86 and a range of $58.86 to $58.86 covering 25 companies (54.7% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy14 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XPH Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.78%OGNOrganon & Co.$13.37+0.2%2.8595 of 5 stars1.57$11.40 -14.7%7Positive News2.76%CORTCorcept Therapeutics$58.30+2.1%4.0499 of 5 stars2.75$70.83 21.5%8Positive NewsAnalyst Upgrade2.67%LQDALiquidia$59.30+3.0%2.6928 of 5 stars2.92$49.33 -16.8%12Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision2.55%AXSMAxsome Therapeutics$232.27-1.3%2.6178 of 5 stars2.90$251.26 8.2%212.50%ELVNEnliven Therapeutics$43.08-1.1%3.3632 of 5 stars2.86$53.17 23.4%7Analyst ForecastAnalyst Revision2.28%MBXMBX Biosciences$35.36-5.7%3.5503 of 5 stars2.77$60.22 70.3%13Analyst ForecastAnalyst Revision2.25%OMEROmeros$13.28-7.6%3.8148 of 5 stars2.83$40.33 203.7%6Earnings ReportAnalyst ForecastHigh Trading Volume2.25%TRVITrevi Therapeutics$15.08-1.2%3.393 of 5 stars3.00$22.90 51.9%122.23%VTRSViatris$17.26-0.6%2.5585 of 5 stars2.38$15.71 -9.0%82.23%JAZZJazz Pharmaceuticals$231.05-0.6%2.384 of 5 stars2.83$230.56 -0.2%18Positive News2.12%INDVIndivior$37.83-1.4%3.7521 of 5 stars3.00$39.33 4.0%7Positive News2.11%ESPREsperion Therapeutics$3.123.3553 of 5 stars2.00$5.54 77.6%8Earnings Report2.06%DFTXDefinium Therapeutics$21.35-3.0%3.0094 of 5 stars3.00$37.92 77.6%15Earnings ReportAnalyst Revision2.06%PRGOPerrigo$10.85-0.5%4.2448 of 5 stars2.00$19.33 78.2%6Analyst Upgrade2.01%RPRXRoyalty Pharma$53.40+0.3%3.7799 of 5 stars3.00$53.71 0.6%71.99%EWTXEdgewise Therapeutics$34.01+0.7%2.3887 of 5 stars2.89$39.67 16.6%9Analyst Revision1.94%NKTRNektar Therapeutics$74.33-2.1%3.0027 of 5 stars2.73$149.63 101.3%11Analyst Revision1.92%NUVBNuvation Bio$4.71-1.6%2.9468 of 5 stars2.70$12.50 165.7%101.90%HRMYHarmony Biosciences$30.76-0.2%4.8262 of 5 stars2.27$40.89 32.9%11Positive News1.89%ANIPANI Pharmaceuticals$79.58-1.6%3.7807 of 5 stars2.88$107.33 34.9%8Trending NewsEarnings ReportInsider Trade1.88%XERSXeris Biopharma$6.38-0.8%3.0391 of 5 stars2.43$10.80 69.3%7Analyst Revision1.84%INVAInnoviva$22.86-1.2%4.1352 of 5 stars2.57$36.20 58.4%71.82%LGNDLigand Pharmaceuticals$218.98-1.0%3.7007 of 5 stars2.88$257.71 17.7%8Earnings ReportInsider Trade1.82%PCRXPacira BioSciences$23.53+2.1%3.1999 of 5 stars2.29$29.40 24.9%71.82%COLLCollegium Pharmaceutical$34.83-0.1%2.7641 of 5 stars2.67$57.50 65.1%6 This page (NYSEARCA:XPH) was last updated on 5/15/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
